188576-49-0

Basic information

• Product Name: TERT-BUTYL 7-HYDROXY-3,4-DIHYDROISOQUINOLINE-2(1H)-CARBOXYLATE
• Synonyms: TERT-BUTYL 7-HYDROXY-3,4-DIHYDROISOQUINOLINE-2(1H)-CARBOXYLATE;7-Hydroxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester
• CAS NO: 188576-49-0
• Molecular Formula: C₁₄H₁₉NO₃
• Molecular Weight: 249.31
• Mol File: 188576-49-0.mol
• Article Data: 16

Chemical Properties

• Melting Point: 140-142.5 °C
• Boiling Point: 391.376°C at 760 mmHg
• Flash Point: 190.497°C
• Appearance: /
• Density: 1.171g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.558
• Storage Temp.: 2-8°C
• PKA: 10.22±0.20(Predicted)
• CAS DataBase Reference: TERT-BUTYL 7-HYDROXY-3,4-DIHYDROISOQUINOLINE-2(1H)-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 7-HYDROXY-3,4-DIHYDROISOQUINOLINE-2(1H)-CARBOXYLATE(188576-49-0)
• EPA Substance Registry System: TERT-BUTYL 7-HYDROXY-3,4-DIHYDROISOQUINOLINE-2(1H)-CARBOXYLATE(188576-49-0)

Safety Data

• Hazardous Substances Data: 188576-49-0(Hazardous Substances Data)

Usage

Uses

tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate is a useful reagent for the preparation of biologically active small molecules.

InChI:InChI=1/C14H19NO3/c1-14(2,3)18-13(17)15-7-6-10-4-5-12(16)8-11(10)9-15/h4-5,8,16H,6-7,9H2,1-3H3

Upstream product

• 30798-64-2 7-hydroxy-1,2,3,4-tetrahydroisoquinoline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 123-91-1 1,4-dioxane 
• 110192-19-3 7-hydroxy-1,2,3,4-tetrahydroisoquinoline hydrobromide 
• 94086-06-3 C₁₆H₁₇NO 
• 937048-76-5 7-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 258515-65-0 7-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylic acid tert-butyl ester 
• 17680-55-6 7-bromo-1,2,3,4-tetrahydroisoquinoline 
• 1700-37-4 3-Benzyloxybenzaldehyde 
• 7651-83-4 isoquinolin-7-ol 
• 591-31-1 3-methoxy-benzaldehyde 
• 43207-78-9 7-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 39989-39-4 7-methoxyisoquinoline 
• 188576-56-9 1,2,3,4-tetrahydro-isoquinolin-7-ol acetate 

Downstream Products

• 1203600-36-5 tert-butyl 7-[({4-[(benzyloxy)methyl]-1-(pyridin-4-yl)piperidin-4-yl}carbonyl)oxy]-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1203600-33-2 tert-butyl 7-{[4-(pyrrolidin-1-ylcarbonyl)benzoyl]oxy}-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1203600-46-7 tert-butyl 7-[(4-{[1-(tert-butoxycarbonyl)piperidin-4-yl]oxy}benzoyl)oxy]-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1203600-48-9 benzyl 4-{4-[({2-[amino(imino)methyl]-1,2,3,4-tetrahydroisoquinolin-7-yl}oxy)carbonyl]phenoxy}piperidine-1-carboxylate trifluoroacetate 
• 247132-98-5 benzyl 4-(2-tert-butoxycarbonyl-1,2,3,4-tetrahydroisoquinolin-7-yloxymethyl)piperidin-1-carboxylate 
• 188576-50-3 7-<(4-(benzyloxy)phenyl)(ethoxycarbonyl)methoxy>-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 158984-83-9 N-tert-butoxycarbonyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline 
• 247133-24-0 8-hydroxy-2,3,4,5-tetrahydro-1H-benz[c]azepine-2-carboxylic acid tert-butyl ester 

Relevant articles and documents

PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST

Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as A2A receptor antagonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as A2A receptor antagonist.

DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS

The invention provides dihydroisoquinoline-2(1H)-carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting HPK1 activity.

Of tetracyclic Anaplastic lymphoma kinase inhibitors (by machine translation)

The invention belongs to the field of medical technology, in particular to general formula (I) as shown in of tetracyclic Anaplastic lymphoma kinase inhibitor, its pharmaceutically acceptable salt or a stereoisomer thereof, wherein R 1, R 2, R 3, R 4, R 5 and A link like defined in the specification. The invention also relates to methods of preparing such compounds, pharmaceutical preparations comprising these compounds and pharmaceutical composition, the compound and, its pharmaceutically acceptable salts or stereoisomers thereof, in the preparation of the treatment and/or prevention of Anaplastic lymphoma kinase-mediated cancer diseases related to the application of the medicament. (by machine translation)